Volume 8: Issue 4

The scientific program of the Pulmonary Hypertension Association is guided by the association's Scientific Leadership Council. The Council includes the following health care professionals:

Vallerie V. McLaughlin, MD, Chair, SLC, University of Michigan Health System, Ann Arbor, Michigan
David B. Badesch, MD, SLC Immediate Past-Chair, University of Colorado Health Sciences Center, Aurora, Colorado
John H. Newman, MD, SLC Vice-Chair, Vanderbilt Medical School, Nashville, Tennessee
Raymond L. Benza, MD, Allegheny General Hospital, Pittsburgh, Pennsylvania
Todd Bull, MD, University of Colorado Health Sciences Center, Denver, Colorado
Richard Channick, MD, Editor-in Chief, Advances in Pulmonary Hypertension

Summaries and commentaries from the section editors present a clinical context for practitioners' application of recently published research relevant to care of patients with pulmonary hypertension. This issue's reviews were prepared by Dr Bull.

Michelle Ogawa, CPNP

Download as Powerpoint
Download Figure

Darci Albrecht, MSW

Download as Powerpoint
Download Figure

Adolescence can represent a challenging period of physical, cognitive, and psychological development. While adolescents struggle to develop self-identity, they must also deal with physiologic and sexual maturation, greater demands to become more independent, and increasing peer pressure to fit in. For children with pulmonary arterial hypertension (PAH), having a chronic and life-limiting disease is likely to create greater obstacles and adversities that may delay their ability to meet age-appropriate developmental milestones.1 The health care system places an added burden on these chronically ill children

To complement this issue's theme, “Living With Pulmonary Hypertension,” a discussion on assisting patients with therapy decisions was led by guest editor Glenna Traiger, RN, MSN, Pulmonary Hypertension CNS, University of California, Los Angeles. The panelists included Karen Frutiger, RN, Clinical Nurse Coordinator, University of Rochester Pulmonary Arterial Hypertension Program, Rochester, NY; Martha Kingman, Nurse Practitioner, University of Texas Southwestern Medical Center, Dallas; and Abby Poms, RRT, Duke University Pulmonary Vascular Disease Program Manager, Duke University Medical Center, Durham, North Carolina.

This edition of the Clinical Trials Update was prepared by section editor Dr Levine. It features a review of the baseline characteristics of the REVEAL (Registry to Evaluate Early And Long-term PAH disease management) Registry™.1 Unlike the clinical trials we have reviewed previously in this section, REVEAL is an important registry of a large cohort of pulmonary arterial hypertension (PAH) patients.

Living with PH: Longer and Better

Editor's Memo

The Scientific Leadership Council of the Pulmonary Hypertension Association

Ask the Expert

Article Reviews

Health-related Quality of Life in Pulmonary Arterial Hypertension

Depression and Pulmonary Arterial Hypertension: Should We be Screening for Depressive Symptoms?

Facilitating Pulmonary Arterial Hypertension Medication Adherence: Patient-centered Management

Adolescence to Adulthood: Safely Transitioning the Adolescent With Pulmonary Arterial Hypertension

Assisting Pulmonary Hypertension Patients and Families With Treatment Decisions

Clinical Trials Update

PHRN Corner

Collaborative Practice

Conference Abstracts

Guest Editor’s Memo

A Roundtable Discussion Addressing Patient-Centered Care and Quality of Life in Patients With Pulmonary Arterial Hypertension

Editor’s Memo

Pulmonary Hypertension Associated With Parenchymal Lung Disease